Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | SL-172154 |
Synonyms | |
Therapy Description |
SL-172154 is a fusion protein that is engineered to target CD47 on tumor cells and CD40 on antigen presenting cells (APCs), which inhibits CD47/SIRPa signaling and potentially results in increased anti-tumor immune response (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
SL-172154 | SL172154|SL 172154|CD172a-Fc-CD40L Chimeric Protein SL-172154 | SL-172154 is a fusion protein that is engineered to target CD47 on tumor cells and CD40 on antigen presenting cells (APCs), which inhibits CD47/SIRPa signaling and potentially results in increased anti-tumor immune response (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04502888 | Phase I | SL-172154 | Ph1 Study of SL-172154 Administered Intratumorally in Subjects With Squamous Cell Carcinoma of the Head and Neck or Skin | Terminated | USA | 0 |
NCT05275439 | Phase I | Azacitidine + SL-172154 + Venetoclax Azacitidine + SL-172154 SL-172154 | Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML | Active, not recruiting | USA | GBR | CAN | 0 |
NCT04406623 | Phase I | SL-172154 | Phase 1 Study of SL-172154 (SIRPalpha-Fc-CD40L) in Subjects With Ovarian Cancer | Completed | USA | 0 |